Image

Early Deresuscitation Strategy Driven by Tissue Perfusion in Renal Replacement Therapy in Patients With Acute Renal Failure

Early Deresuscitation Strategy Driven by Tissue Perfusion in Renal Replacement Therapy in Patients With Acute Renal Failure

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

In Intensive Care Unit (ICU) patients with acute kidney injury (AKI) and treated with renal replacement therapy (RRT) often present a fluid overload which is associated with morbidity (mechanical ventilation duration increase, kidney recovery decrease) and mortality.

Patients' prognostic could be improved by correcting the fluid overload with net ultrafiltration (UFnet) however it may lead to harmful iatrogenic hypovolemia responsible of deleterious ischemic lesions.

In usual practice, UF net prescription are variable and there are different international recommendations. Some observational studies suggest that using a UFnet between 1 et 1.75 mL/kg/h in fluid overloaded patient decrease mortality.

Fluid overload increases morbidity and mortality, particularly in RRT. Studies without RRT argue for an efficacy of management by decreasing the fluid overload .Cohort studies suggest to use a moderate UFnet instead of a low UFnet. Some data from studies on early versus late RRT that relate the fluid balance or correct the fluid overload during the early strategy argue for a beneficial effect of an early deresuscitation strategy

Consequently, the impact of a moderate UFnet (to decrease the fluid overload) compared to a low UFnet (to stabilize the fluid overload) in a randomized interventional study could be assessed.

The study hypothesis is that :

an early fluid overload deresuscitation protocol with a high UFnet (2 ml/kg/h) targeting both the negativation of cumulated fluid balance to reach a dry weight and the maintenance of tissue perfusion.

Compared to

fluid overload deresuscitation protocol with a low UFnet (between 0 and 1 ml/kg/h) to reach a stabilization of cumulated fluid balance without monitoring the tissue perfusion.

could improve overall, renal, hemodynamic and respiratory prognosis in fluid overloaded patients with renal replacement therapy in ICU

Eligibility

Inclusion Criteria:

  1. Acute kidney injury treated by continuous renal replacement therapy in ICU less than 7 days,
  2. At least 1 organ failure during ICU in addition to AKI (oxygen therapy or vascular filling > 1000ml),
  3. Cumulative UF net less than 1000ml before inclusion,
  4. Norepinephrine < 0,5 µg/kg/min,
  5. Absence of hypoperfusion signs,
  6. Fluid overload defined as follows :
    • fluid overload > 5% of base weight (based on cumulative fluid balance or a weight gain) and/or
    • Obvious oedema of the lumbar region or flanks (oedema > 1cm bucket depth).

Exclusion Criteria:

  1. Chronic renal failure hemodialyzed before admission to the ICU,
  2. Mechanical circulatory support (ECMO, LVAD),
  3. Pregnant, child -bearing age or lactating women,
  4. Stroke less than 30 days,
  5. Intestinal ischemia less than 7 days documented non-operated,
  6. Interventional study participation or exclusion period on going,that may interfere with the present study
  7. Guardianship, curatorship or safeguard of justice,
  8. Absence of signature of free and informed consent by the patient and/or relative,
  9. Patients not affiliated to a social security scheme or beneficiaries of a similar scheme

Study details
    Acute Kidney Injury
    Fluid Overload

NCT05817539

Hospices Civils de Lyon

18 May 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.